#161580

PC-3 Ag cell line

Cat. #161580

PC-3 Ag cell line

Cat. #: 161580

Organism: Human

Tissue: Pancreas

Disease: Cancer

Model: Mutant

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: William G Watson

Institute: University College Dublin

Primary Citation: O'Neill et al. Mol Cancer. 2011 Oct 7;10:126. PMID: 21982118

Tool Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: PC-3 Ag cell line
  • Alternate name: PC-3 age matched cell line
  • Cancer: Pancreatic cancer
  • Cancers detailed: Pancreatic cancer
  • Research fields: Cancer
  • Organism: Human
  • Tissue: Pancreas
  • Disease: Cancer
  • Growth properties: Suspension
  • Model: Mutant
  • Crispr: No
  • Products or characteristics of interest: Age matched cell line
  • Description: Docetaxel resistant sub-lines were generated in the androgen-independent (PC-3, DU-145) and sensitive (22RV1) cell lines. One of the main mechanisms of resistance to Docetaxel is the over expression of P-gp which would reduce intracellular concentrations of the drug through increased efflux. Chemoresistant PC-3 cells do not over express P-gp. We demonstrated that the resistance in the PC-3 sublines was independent of P-gp over expression as there were no detectable levels and no effects of the P-gp inhibitor Elacridar on their resistance
  • Application: Mechanisms of resistance to Docetaxe in pancreatic cancer cells
  • Production details: PC-3 resistant sub-lines were generated by initially treating with Docetaxel (Sigma) at 4 nM and 8 nM (suspended in dimethyl sulfoxide (DMSO) (Fluke)) in 75 cm2 flasks for 48 hours. After treatment, the surviving cells were re-seeded into new flasks and allowed to recover for 2-3 weeks. After 5 (at 8 nM) and 7 (at 4 nM) treatments, the dose of docetaxel was increased from 4 nM and 8 nM to 8 nM and 12 nM respectively. The cells underwent a total of 18 treatment cycles at 8 nM and 12 treatment ...

Applications

  • Application: Mechanisms of resistance to Docetaxe in pancreatic cancer cells

Handling

  • Format: Frozen
  • Growth medium: RPMI-1640 medium supplemented with 10% Fetal Bovine Serum (FBS), 50 U/ml penicillin/50 ?g/ml streptomycin and 2 mM L-glutamine
  • Shipping conditions: Dry Ice
  • Storage conditions: Liquid Nitrogen

References

  • O'Neill et al. Mol Cancer. 2011 Oct 7
  • 10:126. PMID: 21982118